Business
BioNTech surges on COVID-19 vaccine sales forecast – The Australian Financial Review
BioNTech and partner Pfizer signed contracts to deliver some 2.2 billion doses of the two-shot vaccine this year and more than…
The technology is also being tested in cancer, in an aim to spur the immune system to fight off tumours. BioNTech has started six new patient trials this year — for a total of 15 experimental drugs in 18 trials — and said it plans to move two more potential…
Continue Reading
-
Business9 hours ago3 of the best ASX shares to buy with $5,000
-
Business22 hours ago3 ASX 200 shares set to dominate the next decade
-
Business4 hours agoUp 29% since April, why is this ASX 200 coal stock tumbling today?
-
Noosa News22 hours agoTwo young girls charged following a string of assaults and robberies in Queensland’s south east